The Retina Radar With Dr. Arshad Khanani on DR, GA, New Mechanisms, and Noninvasive Treatments
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Genentech, a member of the Roche Group; AbbVie Inc.; Astellas; Apellis Pharmaceuticals, Inc.; Opthea; Alimera Sciences, Inc.; EyePoint Pharmaceuticals, Inc.; Neurotech Pharmaceuticals, Inc.; REGENXBIO Inc.; and Ocular Therapeutix, Inc.
Overview
Provider Statement
This continuing education activity is provided by 
Support Statement
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Genentech, a member of the Roche Group; AbbVie Inc.; Astellas; Apellis Pharmaceuticals, Inc.; Opthea; Alimera Sciences, Inc.; EyePoint Pharmaceuticals, Inc.; Neurotech Pharmaceuticals, Inc.; REGENXBIO Inc.; and Ocular Therapeutix, Inc.
Activity Description
Retinal diseases are a leading cause of global vision impairment, driven by an increasing prevalence and the need for more effective treatment. Although clinical trials have shown promising results for various therapies, real-world application often yields less impressive outcomes due to factors like undertreatment and patient nonadherence. New and emerging therapies, particularly for conditions like diabetic macular edema (DME), diabetic retinopathy (DR), and geographic atrophy (GA) secondary to age-related macular degeneration (AMD), aim to reduce the burden of frequent injections through innovative mechanisms and delivery systems. Recent advances include development of promising investigational treatments targeting various molecular pathways. In this CE activity, expert faculty review current and emerging treatment options for DME, DR, GA secondary to AMD, and other retinal diseases. They also assess the latest clinical trial data and real-world studies regarding the management of these conditions.
Target Audience
The intended audience for this activity is US-based ophthalmologists, retina specialists, optometrists, and other healthcare professionals involved in the management of retinal diseases.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Assess current and emerging treatment options that may improve outcomes for patients with DR.
- Describe how new and emerging therapies for GA secondary to AMD can fit into the treatment paradigm to optimize its management.
- Review treatments with new mechanisms of action and clinical data that supports their use in the treatment of retinal diseases.
- Summarize the latest information, emerging clinical trial data, and real-world studies regarding the management of DME.
Activity Chair
Arshad M. Khanani, MD, MA, FASRS
Managing Partner
Director of Clinical Research
Director of Fellowship
Sierra Eye Associates
Clinical Professor of Surgery
University of Nevada, Reno School of Medicine
Reno, NV
Faculty
David S. Boyer, MD
Clinical Professor of Ophthalmology
University of Southern California-Keck School of Medicine
Senior Partner, Retina-Vitreous Associates Medical Group
Los Angeles, CA
Carl J. Danzig, MD, FASRS
Director of Vitreoretinal Services and Retina Clinical Research
Rand Eye Institute
Deerfield Beach, FL
Affiliate Assistant Professor of Clinical Biomedical Science
Charles E. Schmidt College of Medicine
Florida Atlantic University
Boca Raton, FL
Eleonora (Nora) Lad, MD, PhD
Associate Professor of Ophthalmology
Director of Ophthalmology Clinical Research Unit
Director of Grading, Duke Reading Center
Duke University Medical Center
Durham, NC
Carl D. Regillo, MD, FACS
Director, Retina Service
Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Mid Atlantic Retina
Philadelphia, PA
Planner/Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
ACCREDITATION
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, October 31, 2024, to October 30, 2025.
How to Participate in This Activity and Obtain CE Credit
To participate in this activity, you must read the objectives, answer the polling and pretest questions, listen to the podcasts, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 of the 4 posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Disclosures
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
Activity Chair and Faculty report the following relevant financial relationship(s)
David S. Boyer, MD
Consultant: 4DMT, Adverum, Aerpio, Alcon, Alkahest, Allegro, Allergan, Amydis, Annexon, Apellis, AsclepiX, Aviceda, Chengdu Kanghong, Clearside, EyePoint, Genentech/Roche, Glaukos, IVERIC bio, Kala, Kodiak, Lumithera, Nanoscope, Novartis, Ocugenix, Ocular Therapeutix, Oculis, ONL Therapeutics, Oxurion, Perfuse, Perceive, Ray Therapeutics, Recens Medical, Regeneron, Regenxbio, Stealth, Unity
Independent Research Contractor: Adverum, Aerpio, Apellis, AsclepiX, Aviceda, Boehringer Ingelheim, Chengdu Kanghong, Clearside, EyePoint, Gemini, Genentech/Roche, IVERIC bio, Kodiak, Lumithera, Nanoscope, Neurotech, Novartis, Ocular Therapeutix, Oculis, Opthea, Outlook, Ray Therapeutics, Regeneron, Regenxbio, Stealth, Unity
Stock Options: Ray Therapeutics
Carl J. Danzig, MD, FASRS
Consultant: AbbVie, Adverum, EyeBio, Galimedix, Genentech, Iveric Bio, Kodiak, Regenerion, Regenxbio, Roche
Speaker Contracted by Ineligible Company: Genentech/Roche, IVERIC bio/Astellas
Independent Research Contractor: Kodiak, Novartis, Regeneron, Regenxbio, Rezolute, Roche, Unity
Arshad M. Khanani, MD, MA, FASRS
Consultant: 4DMT, AbbVie, Adverum, Alcon, Amgen, Annexin, Annexon, Apellis, Aviceda, Beacon Therapeutics, Clearside, Complement Therapeutics, Exegenesis, EyePoint, Fronterra, Genentech, Gyroscope, i-Lumen, Iveric Bio, Janssen, Kodiak, Kriya, Nanoscope, Novartis, Ocular Therapeutix, Oculis, Ocuphire, Opthea, Oxular, Oxurion, Perfuse, Ray Therapeutics, Regeneron, Regenxbio, RevOpsis, Roche, Sanofi, Stealth, Unity Bio, Vanotech
Speaker Contracted by Ineligible Company: IVERIC bio
Independent Research Contractor: 4DMT, Adverum, Alexion, Annexon, Apellis, Aviceda, EyePoint, Exegenesis, Genentech, Gyroscope, IVERIC bio, Janssen, Kodiak, Neurotech, Ocular Therapeutix, Oculis, Opthea, Oxular, Oxurion, Regenxbio, Roche, Unity Bio, Vanotech
Stock Options: Aviceda, Oculis, Opthea, Perfuse, PolyPhotonix
*Individual Stocks (privately held): RevOpsis
Eleonora (Nora) Lad, MD, PhD
Advisor: 4DMT, Alexion, Allegro, Annexon, Apellis, BioCryst, Blue Rock, Boehringer Ingelheim, Broadwing Bio, Complement Therapeutics, Emmecell, Galimedix, IVERIC bio/Astellas, Janssen, Kriya, LumiThera, Lutronic Vision, Nanoscope, Novartis, Ocular Therapeutix, Osanni Bio, Perceive Bio, Regeneron, Retrotope, Roche, Sanofi, Sitala
Consultant: 4DMT, Alexion, Allegro, Annexon, Apellis, Blue Rock, Boehringer Ingelheim, Broadwing Bio, Complement Therapeutics, Emmecell, Galimedix, IVERIC bio/Astellas, Janssen, Kriya, LumiThera, Lutronic Vision, Nanoscope, Novartis, Ocular Therapeutix, Osanni Bio, Perceive Bio, Regeneron, Retrotope, Roche, Sanofi, Sitala
Independent Research Contractor: Alexion, Apellis, Belite Bio, Boehringer Ingelheim, Gemini, IVERIC bio, Janssen, LumiThera, Neurotech, Novartis, Roche
Stock Options: Osanni Bio
Carl D. Regillo, MD, FACS
Consultant: 4DMT, Adverum, Alcon, Allergan, Annexon, Apellis, Aviceda, Clearside, Cognition Therapeutics, EyePoint, Genentech, Graybug, IVERIC bio, Janssen, Kodiak, Lineage Cell Therapeutics, Merck, Novartis, Ocugen, Ocuphire, OcuTerra, Opthea, Ray, Regeneron, Regenxbio, Stealth BioTherapeutics, Zeiss
Independent Research Contractor: 4DMT, Adverum, Allergan, Annexon, Apellis, Astellas, EyePoint, Genentech, Graybug, Gyroscope, IVERIC bio, Kodiak, Lineage Cell Therapeutics, Notal Vision, Novartis, Ocugen, Opthea, Regeneron, Regenxbio
Stock Options: Aviceda, Ocugen
*Will not discuss business lines or products of company(ies).
Planner/Reviewer reports the following relevant financial relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relevant financial relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
ADA Compliance
In compliance with the Americans with Disabilities Act of 1990, we will make all reasonable efforts to accommodate persons with disabilities. Links to text-based transcripts of these podcasts are available within.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2024 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CE Questions?
Contact us at cme@vindicoCME.com